Genetic Technologies and Verizon IndyCar Series Driver

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing Partnership

MELBOURNE, AUSTRALIA--(Marketwired - Jun 22, 2016) - Genetic Technologies Limited ( ASX : GTG ) ( NASDAQ : GENE ) ("Company"), a molecular diagnostics company specializing in women's health, and provider of BREVAGen plus ®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, announced today an update on its marketing partnership with Verizon IndyCar Series driver, Pippa Mann.

The program commenced with the Indianapolis 500, the largest single day sporting event in the world, in terms of on-site attendance. The event offered significant promotional opportunities throughout the month of May, leading-up to the historic 100th running of the race, which took place on May 29, 2016. Mann is one of only nine female athletes to ever compete in the Indianapolis 500 and the only female driver to start in the race over the past four consecutive years. The BREVAGen plus logo was featured on Mann's #63 Dale Coyne Racing Indy Car supporting Susan G. Komen, the world's largest breast cancer organization, as well as being prominently placed on her racing and promotional apparel. Mann was featured in BREVAGen plus advertising that appeared in the official Indy 500 Program and also in the USA Today special commemorative edition about the race. Mann also participated in a variety of BREVAGen plus promotional activities leading-up to the race at the Indianapolis Motor Speedway, hosted a breast cancer survivor event and promoted BREVAGen plus at public appearances and on her social media platforms.

Additional promotional events that occurred in May with Mann included joining Eutillio Buccilli, Chief Executive Officer of Genetic Technologies Limited at the Nasdaq MarketSite in New York City's Times Square to perform the honorary ringing of the Closing Bell. Whilst in New York, Mann also participated in a media tour, appearing on CNBC Television's "Squawk Box," along with Fox Sports Business, Sirius XM Radio and conducting interviews with Glamour Magazine and Forbes Business Online reporters.

Please visit our website to view our recent news and media appearances .

"We were extremely pleased to be invited to Nasdaq's MarketSite for the ceremonial bell ringing at this exciting time for the Company as we continue to ramp-up commercial activities for BREVAGen plus ," commented Buccilli. "The event had additional meaning to us as it ceremoniously marked, in earnest, the beginning of our partnership with Pippa Mann, a next generation athlete who has demonstrated true conviction and commitment to promoting women's health and in particular, breast cancer awareness."

"It was exciting to kick off my association with Genetic Technologies by going to New York and ringing the closing bell on behalf of the Company," said Mann. "I'm pleased they've chosen me to help promote BREVAGen plus as I believe the test can have a valuable impact on proactively managing women's health, which is near and dear to my heart."

Moving forward, the BREVAGen plus logo will continue to be featured on Mann's racing and promotional apparel, and she will appear in the Company's promotional print, video and social media platforms, promoting BREVAGen plus and its role in her overall advocacy for women's wellness.

As a lead-up to October's Breast Cancer Awareness Month, the back half of calendar year 2016 will feature many appearances by Mann including Fox Sports TV Channels throughout the United States this summer, The Susan G. Komen 2016 Partner Summit in New York City in late June, and Susan G. Komen Race for the Cure events across the U.S.

About Genetic Technologies Limited Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product, BREVAGen plus ®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGen plus improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGen plus expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer. The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGen plus , launched in October 2014, significantly expands the applicable market. The Company markets BREVAGen plus to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com .

About Pippa Mann Having grown up as a race fan, Pippa Mann began her motorsport career in Europe, before moving to the States in 2009 to compete in the Firestone Indy Lights Series. There she became the first female in history to win a pole at the Indianapolis Motor Speedway, and only the second woman ever to win an Indy Lights race. In 2011, Mann became the eighth woman in history to qualify for and race in the Indianapolis 500, and the first British female to do so. Mann has now competed in four Indianapolis 500 races, and is currently the second fastest female qualifier of all time with a four lap average of the Speedway at just under 230mph. Outside of the car Mann is passionate about her partnership with Susan G. Komen®, and about her role as a Wellness Ambassador for Well & Company. She regularly spends time connecting with her fan-base directly through social media interaction, in person appearances and autograph signings, and she strives to inspire young girls to believe in themselves and follow their dreams. Visit www.pippamann.com to learn more.

About Dale Coyne Racing Dale Coyne Racing (DCR) is a Verizon IndyCar Series team based in Plainfield, IL, about 40 miles southwest of downtown Chicago. The team has participated in every season of the INDYCAR/Champ Car World Series since 1984, making this their 32nd season of competition. DCR earned its third IndyCar win with a victory in Detroit in 2013 where they finished with both cars on the podium. The team was able to win for a fourth straight season in 2014 when visiting victory lane in Houston. Team Owner Dale Coyne is a true racer with a long history in racing. As an Indy car driver for five years, and a team owner since 1984, he has more than 30 years of experience in open-wheel racing. Coyne is a Midwestern entrepreneur who designed and built Route 66 Raceway in Joliet, IL. Dale Coyne and Tony George, along with International Speedway Corporation (ISC), expanded the facility by forming a partnership and building Chicagoland Speedway. Coyne served as president of the facility through its construction and opening season, and served on its management committee until its eventual buyout by ISC in 2007.

Safe Harbor Statement Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act . The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

FOR FURTHER INFORMATION PLEASE CONTACT Mr. Eutillio Buccilli Executive Director & Chief Executive Officer Genetic Technologies Limited + 61 3 8412 7050 Candice Knoll (USA) Blueprint Life Science Group +1 (415) 375 3340, Ext. 4

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 28

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 25

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 64

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 192

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 31

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 328

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 195

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 13

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 16

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading

Top 5 Most Recently Viewed Articles

GM Partners with Barclays to Enhance Credit Card Offerings

Updated Category News Views 71

General Motors and Barclays Sign a Strategic Partnership General Motors (NYSE: GM) and Barclays have recently announced a significant long-term partnership that focuses on credit card services. This strategic agreement reflects both companies' commitment to enhancing customer experience and providing innovative financial solutions. Benefits of the New Credit Card...

Continue Reading
Enbridge Inc. Declares 3% Increase in Quarterly Dividend

Updated Category News Views 126

Enbridge Inc. Increases Quarterly Dividend by 3% Enbridge Inc. (TSX: ENB) has made a significant announcement regarding its quarterly dividend. The company declared a quarterly dividend of $0.9425 per common share, signaling a 3% increase from previous rates. This notable hike reflects Enbridge's commitment to shareholder value and marks the thirtieth consecutive year of...

Continue Reading
Jefferies Advises Caution on Biotech-Related CRO Investments

Updated Category News Views 545

CROs Confront Challenges as Biotech Market Slows In a recent analysis, Jefferies is advising investors to rethink their investments in contract research organizations (CROs), particularly those focused on biotech and early-stage research. This caution comes as the demand in the biotech sector has noticeably declined. Financial Struggles Affects Companies Jefferies has...

Continue Reading
Remarkable Cost Savings with QUELIMMUNE for Pediatric AKI

Updated Category News Views 137

Significant Economic Impact of QUELIMMUNE Therapy SeaStar Medical Holding Corporation (Nasdaq: ICU), a pioneering healthcare company, has recently published a health economic analysis that underscores the substantial financial benefits of its QUELIMMUNE therapy for pediatric patients suffering from Acute Kidney Injury (AKI). The analysis highlights an estimated average...

Continue Reading
SKF Invites Fans to Revitalize Tattoos with Brand Update

Updated Category News Views 228

SKF Invites Fans to Revitalize Tattoos with Brand Update SKF has taken an impactful step to modernize its brand identity, showcasing a fresh and dynamic look aimed at connecting with its audience more effectively. This update marks the company's first significant change to its logo since its inception in 1908, highlighting the dedication to innovation while respecting its...

Continue Reading